New research reveals that individuals who discontinue new GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight much more quickly than those who stop traditional lifestyle programs.
Findings released in a leading health publication demonstrates that while overweight people often shed substantial amounts of their total mass while on the medication, the mass comes back at an estimated rate of nearly a kilo each month upon discontinuation.
"Individuals buying such treatments need to be informed of the potential of quick weight regain when the treatment ends," stated lead investigator Dr. Susan Jebb.
Such speed of recovery suggests a return to original weight within about 18 months.
Comparing Approaches
The research, which examined 37 of trials involving over 9,000 of participants, contrasted the effects of GLP-1 agonists with other pills.
Researchers point out that individuals who shed pounds through lifestyle changes alone typically experience a slower creep back—around 0.1 kg a month—once they finish.
The Reason for the Quick Regain
Doctors propose the mode of action of the injections accounts for the amplified regain.
GLP-1 drugs mimic a natural hormone called glucagon-like peptide-1, which controls hunger.
"Long-term administration of GLP-1 levels several times higher than normal may cause the system to generate a reduced amount of its own natural hormone, and may also reduce responsiveness to its actions," noted Dr. Adam Collins, a nutrition researcher.
"Stopping of this hormone supplement means appetite is no longer kept in check, making excessive eating far more likely."
An Ongoing Disease?
Medical guidelines advise the injections for people with obesity-related health risks, alongside prescribed lifestyle changes.
A number of clinicians argue that, considering the high risk of relapse, the treatment might need to be long-term.
This perspective is supported by drug manufacturers, who state that the findings "highlight the long-term character of excess weight," similar to managing diseases like diabetes.
User Testimonies
Users who have come off the jabs report a intense return of hunger.
"I experienced a trigger that goes on and you become extremely hungry," recalled a patient.
This difficulty is compounded if individuals have not adopted permanent dietary or behavioural changes during treatment.
Widespread Adoption
Figures indicate that millions of people in the UK have tried weight-loss jabs in the past year, with interest remaining high.
- Use is higher among women compared to men.
- The middle-aged demographic shows the highest level of interest.
- Many access the medications through private prescriptions rather than public health services.
Ultimately, researchers emphasize that while these medications are potent tools for shedding pounds, they are not a magic fix and long-term success relies on integrated lifestyle management.
